PRG Science & Technology Co., Ltd.
FDA Authorizes Phase 2a Trial of Progerinin for Hutchinson-Gilford Progeria Syndrome
• The FDA has authorized a Phase 2a clinical trial for Progerinin, a novel drug developed by PRG Science & Technology for Progeria treatment.
• The trial will evaluate Progerinin in combination with Zokinvy, the current standard of care, in 10 patients with Progeria and Progeroid Laminopathies.
• Progerinin has shown promise in preclinical studies, potentially increasing lifespan in a Progeria mouse model by 50%.
• This trial represents a collaborative effort between PRG S&T, The Progeria Research Foundation, Boston Children’s Hospital, and Amarex CRO.
© Copyright 2025. All Rights Reserved by MedPath